Trihia, H., Murray, S., Price, K., et al. (2003) Ki-67 Expression in Breast Carcinoma: Its Association with Grading Systems, Clinical Parameters, and Other Prognostic Factors—A Surrogate Marker? Cancer, 97, 1321-1331.
http://dx.doi.org/10.1002/cncr.11188

has been cited by the following article:

• TITLE: Comparing Oncotype DX Recurrence Score Categories with Immunohistochemically Defined Luminal Subtypes

  AUTHORS: Yoshio Mizuno, Hiromi Fuchikami, Naoko Takeda, Junichi Yamada, Yuko Inoue, Hiroshi Seto, Kazuhiko Sato

  KEYWORDS: Breast Cancer, Oncotype DX, Ki-67, Standardized Assessment

  JOURNAL NAME: Journal of Cancer Therapy, Vol.7 No.3, March 22, 2016

  ABSTRACT: Background: At the 13th St Gallen International Breast Cancer Conference in 2013, a new definition of luminal A-like and luminal B-like breast cancer was proposed, involving the expression of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67. We examined the rate of concordance between the risk groups using the Oncotype DX recurrence score (RS) and the previous and newly proposed luminal subtypes with the standardized Ki-67 assessment. Method: The relationship between a previously and newly proposed, immunohistochemically defined luminal A and B subtype with the Oncotype DX RS of 41 cases of T1-2 N0-1 M0 (ER positive, HER2 negative) breast cancer was assessed. We first classified the patients into the previously defined luminal A and B subtypes, according to the level of Ki-67 as either “low” (